Is AbbVie Stock a Buy Now? [Yahoo! Finance]
Cerevel Therapeutics Holdings, Inc. (CERE)
Company Research
Source: Yahoo! Finance
exclusivity last year, and sales plummeted as cheaper generic alternatives entered the market. So, why has AbbVie stock soared nearly 30% over the past three months to new all-time highs? More importantly, have investors missed their opportunity to buy the stock and still see satisfactory investment returns? AbbVie's management has put on a masterclass in executing its transition away from a patent-protected Humira, and it makes the stock a compelling long-term investment idea. Here is what you need to know. Life after Humira looks great AbbVie rode Humira's success for years. The mega-blockbuster drug did $21 billion in sales in 2022, over a third of AbbVie's companywide revenue. Pharmaceuticals enjoy a monopoly while their patents are in effect, which bars competition from copying them. Those patents expire eventually, which happened to Humira in 2023. Global Humira sales in Q4 came in 40% less than the prior year. That seems scary, knowing how important Humira was enter
Show less
Read more
Impact Snapshot
Event Time:
CERE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERE alerts
High impacting Cerevel Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERE
News
- Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study [Yahoo! Finance]Yahoo! Finance
- Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
- Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s DiseaseGlobeNewswire
- Tavapadon for Parkinson's Disease for 7MM: Market Size, Forecast, and Emerging Insights 2019-2032 - Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan [Yahoo! Finance]Yahoo! Finance
- AbbVie slips after revising guidance to reflect earnings impact [Seeking Alpha]Seeking Alpha
CERE
Earnings
- 11/1/23 - Beat
CERE
Sec Filings
- 4/26/24 - Form 10-K/A
- 4/3/24 - Form 4
- 4/1/24 - Form 144
- CERE's page on the SEC website